Table 3Â The pooled OR of POLEmut ECs according to clinicopathology characteristics
Clinicopathological characteristics in EC | Pooled OR (95% CI) | P for pooled OR | No. of studies | I2 (95% CI), (%) | P for I2 | Model | Egger’s test |
|---|---|---|---|---|---|---|---|
EEC vs. NEEC | 1.35 (0.88–2.08) | 0.1719 | 22 | 49.6 (17.4–69.2) | 0.0047 | Random effects | z = 0.98693, P = 0.3237 |
Grade: 1–2 vs. 3 | 0.51 (0.36–0.73) | 0.0002 | 22 | 53.5 (24.6–71.3) | 0.0016 | Random effects | z = −0.14099, P = 0.8879 |
FIGO stage: I-II vs. III-IV | 1.91 (1.29–2.83) | 0.0013 | 28 | 41.4 (8.0–62.7) | 0.0125 | Random effects | z = 0.19757, P = 0.8434 |
LVSI: present vs. absent | 0.98 (0.77–1.25) | 0.8644 | 17 | 15.4 (0.0–51.8) | 0.2727 | Fixed effect | z = −1.6477, P = 0.09941 |
Myometrial invasion: ≥50% vs. < 50% | 0.66 (0.50–0.86) | 0.0025 | 10 | 0.0 (0.0–42.7) | 0.7489 | Fixed effect | z = −0.98387, P = 0.3252 |
Lymph node status: present vs. absent | 1.01 (0.65–1.57) | 0.9641 | 7 | 23.0 (0.0–65.8) | 0.2537 | Fixed effect | z = −1.0513, P = 0.2931 |
Clinical risk stratification: high vs. low | 1.21 (0.73–2.01) | 0.4678 | 5 | 0.0 (0.0–75.4) | 0.4966 | Fixed effect | z = 0, P = 1 |
Adjuvant therapy: yes vs. no | 1.16 (0.88–1.54) | 0.2939 | 14 | 0.0 (0.0–41.7) | 0.6918 | Fixed effect | z = −0.27372, P = 0.7843 |